跳至主要内容
临床试验/NCT04576169
NCT04576169招募中不适用

TREatment of Triangular FibrOcaRtilage ComplEx Ruptures (REINFORCER): Protocol for Randomized, Controlled, Blinded, Efficacy Trial of Triangular Fibrocartilage Complex Tears

Tampere University Hospital9 个研究点 分布在 3 个国家目标入组 204 人开始时间: 2020年10月27日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
204
试验地点
9
主要终点
Patient-Rated Wrist Evaluation (PRWE)

研究概览

简要总结

The trial is a multicentre, randomized, superiority, controlled, participant and outcome assessor (debridement versus placebo surgery randomization cohort) and trialist blinded (both arms) superiority, umbrella trial with two randomized cohorts (1. debridement or placebo surgery, 2. repair or physiotherapy) which both include two 1:1 parallel arms. The primary objective is to investigate the superiority of 1) debridement over placebo surgery and 2) repair over physiotherapy in two randomized cohorts using Patient-Rated Wrist Evaluation (PRWE) at one year post randomisation as the primary outcome.

详细描述

Triangular fibrocartilage complex (TFCC) injuries are often considered the cause of ulnar wrist pain. TFCC lesions can be traumatic or degenerative according to classification suggested by Palmer and Atzei. Primary treatment is conservative, but if symptoms persist, operative treatment is an option. Depending on the morphology of the tear, the treatment can be either debridement or repair. Trialists have observed improvement of symptoms after TFCC repair but all these trials are observational cohorts without proper controls. Efficacy of surgery has not been studied in randomized controlled trial (RCT) setting.

The investigators planned a multicentre, randomized, superiority, controlled, participant and outcome assessor (debridement versus placebo surgery randomisation cohort) and trialist blinded (both arms) superiority, umbrella trial with two randomized cohorts which both include two 1:1 parallel arms. Participants in the first cohort (central or radial TFCC tear) will undergo randomization to either arthroscopic debridement or placebo surgery. In the second cohort (peripheral TFCC tear), participants will be randomized to arthroscopic/open TFCC repair or physiotherapy. Our primary objective is to investigate the superiority of 1) debridement over placebo surgery for central (Palmer 1A) and radial (Palmer 1D) TFCC tears, and 2) repair over non-operative treatment (physiotherapy) for ulnar (Palmer 1B) TFCC tears in two randomized cohorts using Patient-Rated Wrist Evaluation (PRWE) at one year post randomisation as the primary outcome.

Institutional Review Board (IRB) of Tampere university hospital has approved the study protocol. All participants will give written informed consent. The results of the trial will be disseminated as published articles in peer-reviewed journals.

Outcome measures for different studies are often derived from what clinicians, rather than patients, thinks to be important. The investigators chose to base the efficacy assessment on the measure of patient's subjective disability and pain.

There is no clear evidence of the efficacy of the treatments (debridement and repair). It is justified and ethically correct to compare these treatments to placebo surgery and physiotherapy. Placebo surgery and physiotherapy are less invasive than debridement and repair and because of this are even safer to patients than comparable treatments.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

盲法说明

Operating surgeon, operating theatre staff, coordinating research assistant (CRA), and research assistants (RA) cannot be blinded to the allocation. In central or radial tear randomization cohort, outcome assessors will be blinded and they will not participate in the care at any other point in the trial, except during follow-up visits. The participants are also blinded, resulting in a triple-blinded randomization cohort since also trialist are blinded in data analysis phase as in foveal tear randomization cohort. In the ulnar tear cohort, randomization cannot be blinded due to differing postoperative treatment.

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Ulnar sided wrist pain
  • •Age more than 18 years
  • •Suspicion of TFCC tear in clinical examination
  • •Ability to fill the Danish, Finnish or Swedish versions of questionnaires
  • •Symptom duration more than 3 months, and unsuccessful non-operative treatment
  • •Central (Palmer 1A), ulnar (Palmer 1B) or radial (Palmer 1D) TFCC tear explaining the pain in arthroscopy

排除标准

  • •Gross instability of DRUJ which will be defined as "obvious instability in clinical examination in each forearm and wrist position"
  • •Distal (Palmer 1C) TFCC tear in arthroscopy
  • •Ulnocarpal or DRUJ arthrosis (Atzei class 5)
  • •Ulnar variance ≥ +2 mm in x-ray
  • •Age above 65 years
  • •Rheumatoid arthritis or other inflammatory disease effecting radio- or ulnocarpal or DRUJ
  • •Lunotriquetral instability diagnosed in arthroscopy
  • •ECU instability
  • •Massive tear and degenerated edges or frayed tear which fails suture (Atzei class 4A-4B)

研究组 & 干预措施

Central or Radial Tear: Arthroscopic debridement

Experimental

Arthroscopic debridement

干预措施: Arthroscopic Debridement (Procedure)

Central or Radial Tear: Sham surgery

Placebo Comparator

Diagnostic arthroscopy only (placebo surgery).

干预措施: Placebo surgery (Procedure)

Ulnar Tear: Arthroscopic or open repair

Experimental

Arthroscopic or open repair

干预措施: Arthroscopic or Open Repair (Procedure)

Ulnar Tear: Physiotherapy

Active Comparator

Diagnostic arthroscopy and physiotherapy

干预措施: Physiotherapy (Procedure)

结局指标

主要结局

Patient-Rated Wrist Evaluation (PRWE)

时间窗: 10 year follow-up, primary time point at 1 year

The PRWE questionnaire is a wrist-specific instrument comprising a 15-item questionnaire assessing pain and disability in daily living. PRWE provides a score ranging from 0 (best) to 100 (worst). This wrist-specific tool demonstrates good reliability, validity, and responsiveness. Translation and validation have been conducted for Danish, Finnish, and Swedish languages. In interpreting the results, we will employ the Minimally Important Difference (MID) value of 14. PRWE as secondary outcome will be measured at all the other time points (6 months, 2, 5 and 10 years) than primary outcome.

次要结局

  • Quality of life (EQ-5D-3L)(10 year follow-up)
  • Adverse and serious adverse events(10 year follow-up)
  • Global improvement(10 year follow-up)
  • Pain in activity(10 year follow-up)
  • Grip strength(2 year follow-up)
  • ROM of forearm and wrist(2 year follow-up)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jarkko Jokihaara

Associate professor of hand surgery

Tampere University Hospital

研究点 (9)

Loading locations...

相似试验